Condition: Myelodysplastic Syndromes · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Sponsor: Kirsten Grønbæk
This is a multicentre, randomized, parallel-group, placebo-controlled, double-blind phase 2 study of the efficacy and safety of oral vitamin C supplement in combination with azacitidine in patients with higher-risk MDS, CMML-2 or low-blast count AML. The primary purpose is to investigate if oral vitamin C supplementation to azacitidine, compared with azacitidine + placebo, can increase the effectiveness of epigenetic therapy in patients with higher-risk myeloid malignancies, who are not candidates for allogeneic hematopoietic stem cell transplantation.
This description comes directly from the study's public registry record.
Kirsten Grønbæk, Prof., MD · +45 35 45 60 86 · kirsten.groenbaek@regionh.dk
Krista Smidt Bech, BSc, Nurse · +45 35 45 60 80 · krista.smidt.bech.01@regionh.dk
Always discuss trial participation with your own doctor first.
| Aalborg University Hospital | Aalborg, Denmark | Recruiting |
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Herlev University Hospital | Copenhagen, Denmark | Recruiting |
| Odense University Hospital | Odense, Denmark | Active Not Recruiting |
| Zealand University Hospital | Roskilde, Denmark | Terminated |
| Sahlgrenska University Hospital | Gothenburg, Sweden | Recruiting |
| Skåne University Hospital | Lund, Sweden | Recruiting |
| Karolinska University Hospital | Stockholm, Sweden | Recruiting |
| Uppsala University Hospital | Uppsala, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03999723